GSK (NYSE:GSK) Updates FY 2024 Earnings Guidance

GSK (NYSE:GSK) issued an update on its FY 2024 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 2.120-2.160 for the period, compared to the consensus earnings per share estimate of 3.960. The company issued revenue guidance of $41.2 billion-$41.2 billion, compared to the consensus revenue estimate of $39.6 billion.

GSK Stock Up 0.3 %

NYSE:GSK traded up $0.15 during midday trading on Friday, reaching $43.50. 4,048,068 shares of the stock traded hands, compared to its average volume of 3,498,257. GSK has a 12-month low of $33.33 and a 12-month high of $43.84. The business has a 50-day moving average of $41.87 and a two-hundred day moving average of $39.14. The company has a debt-to-equity ratio of 1.15, a quick ratio of 0.62 and a current ratio of 0.87. The stock has a market capitalization of $90.15 billion, a PE ratio of 15.76, a price-to-earnings-growth ratio of 1.49 and a beta of 0.65.

GSK (NYSE:GSK) last issued its quarterly earnings results on Wednesday, January 31st. The pharmaceutical company reported $0.72 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.04). The company had revenue of $10 billion for the quarter, compared to analyst estimates of $9.79 billion. GSK had a net margin of 14.62% and a return on equity of 51.54%. On average, equities analysts forecast that GSK will post 4.13 earnings per share for the current fiscal year.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, July 11th. Shareholders of record on Friday, May 17th will be issued a $0.3762 dividend. This is a boost from GSK’s previous quarterly dividend of $0.36. The ex-dividend date is Thursday, May 16th. This represents a $1.50 dividend on an annualized basis and a yield of 3.46%. GSK’s payout ratio is presently 57.61%.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the stock. Citigroup upgraded shares of GSK from a neutral rating to a buy rating in a research report on Tuesday, February 13th. Guggenheim upgraded shares of GSK from a neutral rating to a buy rating in a research report on Monday, March 4th. Finally, Morgan Stanley initiated coverage on shares of GSK in a research report on Tuesday, January 23rd. They issued an equal weight rating on the stock. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of Moderate Buy.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.